These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25077897)

  • 1. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
    Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
    Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.